Amicus Therapeutics Inc. [NASDAQ: FOLD] jumped around 0.29 points on Wednesday, while shares priced at $9.00 at the close of the session, up 3.33%. The company report on May 21, 2021 that Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases.
Amicus Therapeutics (Nasdaq: FOLD), announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases (ICNMD) being held virtually, May 21-22 and 28-29, 2021.
Amicus Therapeutics Inc. stock is now -61.02% down from its year-to-date (YTD) trading value. FOLD Stock saw the intraday high of $9.03 and lowest of $8.72 per share. The company’s 52-week high price is 25.39, which means current price is +3.69% above from all time high which was touched on 01/06/21.
Compared to the average trading volume of 2.99M shares, FOLD reached a trading volume of 6092917 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Amicus Therapeutics Inc. [FOLD]?
UBS have made an estimate for Amicus Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 21, 2021. The new note on the price target was released on April 14, 2021, representing the official price target for Amicus Therapeutics Inc. stock. Previously, the target price had yet another raise to $13, while Stifel analysts kept a Hold rating on FOLD stock.
The Average True Range (ATR) for Amicus Therapeutics Inc. is set at 0.36, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 9.17. The Price to Book ratio for the last quarter was 9.47, with the Price to Cash per share for the same quarter was set at 1.54.
How has FOLD stock performed recently?
Amicus Therapeutics Inc. [FOLD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.45. With this latest performance, FOLD shares dropped by -10.80% in over the last four-week period, additionally sinking by -59.80% over the last 6 months – not to mention a drop of -27.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 41.36, with the RSI for the last a single of trading hit 42.06, and the three-weeks RSI is set at 40.22 for Amicus Therapeutics Inc. [FOLD]. The present Moving Average for the last 50 days of trading for this stock 9.66, while it was recorded at 8.96 for the last single week of trading, and 15.68 for the last 200 days.
Amicus Therapeutics Inc. [FOLD]: Deeper insight into the fundamentals
Amicus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 5.00.
Earnings analysis for Amicus Therapeutics Inc. [FOLD]
With the latest financial reports released by the company, Amicus Therapeutics Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 23.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FOLD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amicus Therapeutics Inc. go to -1.00%.
Insider trade positions for Amicus Therapeutics Inc. [FOLD]
There are presently around $2,507 million, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 24,387,053, which is approximately 2.271% of the company’s market cap and around 1.00% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 22,861,329 shares of the stock with an approximate value of $205.75 million in FOLD stocks shares; and BLACKROCK INC., currently with $193.7 million in FOLD stock with ownership of nearly -1.625% of the company’s market capitalization.
149 institutional holders increased their position in Amicus Therapeutics Inc. [NASDAQ:FOLD] by around 44,117,896 shares. Additionally, 144 investors decreased positions by around 45,858,909 shares, while 27 investors held positions by with 188,592,844 shares. The mentioned changes placed institutional holdings at 278,569,649 shares, according to the latest SEC report filing. FOLD stock had 50 new institutional investments in for a total of 12,032,210 shares, while 65 institutional investors sold positions of 15,132,586 shares during the same period.